Intraprocedural Superior Hypogastric Nerve Block Allows Same-Day Discharge following Uterine Artery Embolization

J Vasc Interv Radiol. 2020 Mar;31(3):388-392. doi: 10.1016/j.jvir.2019.08.017. Epub 2020 Jan 23.

Abstract

In a single-arm, nonrandomized, retrospective case-control study, 39 patients (mean age, 44 y) who underwent elective outpatient uterine artery embolization with the use of superior hypogastric nerve block (SNHB) for pain control over a period of 3 years were identified. Technical success of SNHB was 87%. Of the 34 patients who received SNHB, 97% did not need a patient-controlled analgesia pump. The median opioid requirement for the 17 patients who needed opioid agents was 7.5 morphine milligram equivalents (interquartile range [IQR], 10). The median length of stay was 2.2 hours (IQR, 1.7 h). SHNB offers a safe and effective intervention that significantly reduces pain and the need for opiate agents and allows same-day discharge after uterine artery embolization.

MeSH terms

  • Adult
  • Analgesia, Patient-Controlled
  • Analgesics, Opioid / administration & dosage
  • Female
  • Humans
  • Hypogastric Plexus*
  • Leiomyoma / diagnostic imaging
  • Leiomyoma / therapy*
  • Length of Stay*
  • Nerve Block* / adverse effects
  • Pain / diagnosis
  • Pain / etiology
  • Pain / prevention & control*
  • Pain Measurement
  • Patient Discharge*
  • Retrospective Studies
  • Time Factors
  • Treatment Outcome
  • Uterine Artery Embolization* / adverse effects
  • Uterine Neoplasms / diagnostic imaging
  • Uterine Neoplasms / therapy*

Substances

  • Analgesics, Opioid